# Data Sheet (Cat.No.T13563)

TargetMol

AZ-1355

## Chemical Properties



CAS No. : 75451-07-9

Formula: C17H17NO4

Molecular Weight: 299.32

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

## Biological Description

| | |
|---|---|
| Description | AZ-1355 is a novel dibenzoxepine derivative with lipid-lowering properties. |
| Targets(IC50) | Prostaglandin Receptor |
| In vivo | AZ-1355 consistently decreases serum total cholesterol (TC) in Triton-induced hyperlipidemic mice at a dose of 150 mg/kg. At a lower dose of 50 mg/kg, it significantly lowers serum triglycerides (TG), while a 100 mg/kg dose effectively reduces both serum TC and TG in rats. Additionally, the 100 mg/kg dosage diminishes total liver TC in rats consuming a CE-2 diet, and a 50 mg/kg dose not only reduces liver TC in rats on a high-fat diet but also decreases total hepatic TG in CE-2 fed rats[1]. |
| Cell Research | The lipid-lowering profile in rodents AZ-1355, A New Dibenzoxazepine Derivative |
| Animal Research | AZ-1355 (150 mg/kg) reproducibly lowers serum total cholesterol (TC) in the Triton hyperlipidemic mice. AZ-1355 (50 mg/kg) significantly reduces serum TG and the 100 mg/kg dose results in serum TC and TG reduction in rats. AZ-1355 (100 mg/kg) reduces total liver TC in rats fed CE-2, and the 50 mg/kg dose reduces hepatic TC in rats fed the high-fat diet on both bases, and it also reduces the total hepatic TG of the CE-2 fed rats. |

## Solubility Information

| | |
|---|---|
| Solubility | DMSO: 22.5 mg/mL (75.17 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.34 mM),Sonication is recommended.<br>*Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.* |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 3.3409 mL | 16.7045 mL | 33.4091 mL |
| 5 mM | 0.6682 mL | 3.3409 mL | 6.6818 mL |
| 10 mM | 0.3341 mL | 1.6705 mL | 3.3409 mL |
| 50 mM | 0.0668 mL | 0.3341 mL | 0.6682 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Wada S, et al. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative. Atherosclerosis. 1981 Nov-Dec;40(3-4):263-71.